At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 182 enrolled
Drug / intervention
Venofer +1 moredrug
Likely dose
Venofer 500 mg IV infusion over 3.5-4 hours on Days 0 and 14, or 200 mg IV injections over 2-5 minutes on 5 occasions from Day 0 to Day 14; or Ferrous Sulfate 325 mg orally three times daily for 56 daysAI-extracted
Key inclusion· 3
- ✓Hemoglobin ≤11.5 g/dL
- ✓Renal anemia confirmed
- ✓Stable dose or not receiving EPO
Key exclusion· 5
- ✕IV iron received within last 6 months
- ✕Chronic infection, malignancy, or major surgery within last month
- ✕Blood transfusion within last 2 months
- ✕Significant blood loss within last 3 months
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia
In Brief
A Phase 3 clinical trial evaluating Venofer and Ferrous Sulfate for Anemia. Completed, enrolled 182 participants across 1 site.
Detailed Summary
To assess the safety and efficacy of two forms of iron therapy for the treatment of anemia in non-dialysis dependent, chronic renal failure in patients receiving or not receiving erythropoietin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2003
Primary CompletionOct 2004
First PostedOct 2005
TodayJul 2026
First PostedOct 12, 2005
Enrollment StartAug 1, 2003
Primary CompletionOct 1, 2004
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 20.7 years ago
Interventions
Venoferdrug
iron sucrose injection; 500 mg intravenous (IV) infusion administered over 3.5-4 hours on Days 0 and 14, or 200 mg injections administered over 2-5 minutes on 5 different occasions from Day 0 to Day 14.
Ferrous Sulfatedrug
oral iron tablets; 325 mg three times a day orally for 56 days